|
|
|
|
Prostat
is a treatment for Benign prostatic hyperplasia (BPH) and chronic non-bacteria prostatitis, the most common urinary diseases among mature men. Prostat is an effective BPH therapy with low adverse effects. Prostat is also the only approved therapy for prostatitis, a difficult to treat condition, almost as common as BPH. Recent scientific finding indicate that Prostat's anti-inflammatory action may actually slow the onset of BPH and therefore be an effective prophylactic for the onset fo that condition. Detail>> |
| |
|
|
ShenNiTing (Tolterodine)
is indicated for the treatment of patients with overactive bladder (OAB). OAB is a condition where you have frequent and strong urges to go to the bathroom (urinate). This condition affects a large percentage of mature women and some men. In men, OAB can be associated with BPH. OAB can be an embarrassing condition that can have dramatic affects on the quality of day to day life. SheNiTing acts by calming and controlling frequent contractions of the bladder muscle, the cause of the urge to urinate. Detail>> |
| |
|
|
Naftopidil
is a treatment for BPH. Naftopidil is an ɑ1-receptor blocker and has a different mode of action compared to Prostat. It is indicated in cases where multiple drug therapies are indicated to releave the symptoms of BPH. Detail>> |
| |
|
|
Cetirizine
is the fourth addition to a new generation of allergy medications called "non- sedating" antihistamines or histamine (H-1) receptor blockers. These new antihistamines are called non-sedating because they cause less sedation than their predecessors; however, cetirizine is more sedating than the other non-sedating antihistamines.
Detail>> |
| |
|
|
Finasteride
is applied to the treatment of symptoms of benign prostatic hyperplasia (BPH): To improve the symptoms. Reduce the risk of acute urinary retention. Reduce the need for transurethral resection of prostate (TURP) and prostatectomy risk. Detail>> |
| |
|
|
|
